We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+71.93%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$766M
AUM Growth
+$254M
Cap. Flow
+$25.8M
Cap. Flow %
3.37%
Top 10 Hldgs %
55.55%
Holding
68
New
13
Increased
17
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$7.81M
2
TCDA
Tricida, Inc. Common Stock
TCDA
+$7.36M
3
FSDC
FS Development Corp. Class A Common Stock
FSDC
+$7.27M
4
CYTK icon
Cytokinetics
CYTK
+$6.84M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$5.6M

Top Sells

Rank Stock Value
1
ATXI
Avenue Therapeutics, Inc. Common Stock
ATXI
+$10.7M
2
APTO
Aptose Biosciences, Inc.
APTO
+$5.22M
3
FULC icon
Fulcrum Therapeutics
FULC
+$4.11M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$3.76M
5
MGNX icon
MacroGenics
MGNX
+$3.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRA
51
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.21M 0.16%
+75,379
New +$1.05M
AMRN
52
Amarin Corp
AMRN
$297M
$1.1M 0.14%
11,250
– –
FULC icon
53
Fulcrum Therapeutics
FULC
$294M
$1.03M 0.14%
88,300
-363,700
-80% -$4.11M
GYRE icon
54
Gyre Therapeutics
GYRE
$708M
$939K 0.12%
+19,840
New +$859K
AKUS
55
DELISTED
Akouos Inc
AKUS
$901K 0.12%
+45,459
New +$886K
ATXS
56
DELISTED
Astria Therapeutics
ATXS
$402K 0.05%
+31,292
New +$558K
DNTH icon
57
Dianthus Therapeutics
DNTH
$6.24B
$375K 0.05%
+2,988
New +$339K
AVEO
58
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$339K 0.04%
+58,800
New +$337K
BLRX
59
BioLineRX
BLRX
$12.1M
$42K 0.01%
417
– –
CDTX
60
DELISTED
Cidara Therapeutics
CDTX
– –
-48,533
Closed -$2.77M
CRNX icon
61
Crinetics Pharmaceuticals
CRNX
$9B
– –
-240,000
Closed -$3.76M
NERV icon
62
Minerva Neurosciences
NERV
$245M
– –
-95,925
Closed -$2.44M
OM icon
63
Outset Medical
OM
$76.9M
– –
-3,000
Closed -$2.25M
SYRE icon
64
Spyre Therapeutics
SYRE
$8.25B
– –
-15,000
Closed -$2.66M
XFOR icon
65
X4 Pharmaceuticals
XFOR
$419M
– –
-2,500
Closed -$508K
PVLA
66
Palvella Therapeutics
PVLA
$2.17B
– –
-1,813
Closed -$300K
ATXI
67
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
– –
-875
Closed -$10.7M
ONCT
68
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-9,727
Closed -$331K
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2020 Portfolio in Review

As of Q4 2020, Opaleye Management held 68 positions worth $766M, up 50% from $511M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opaleye Management deployed $25.8M of net new capital in Q4 2020, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was Tricida, Inc. Common Stock: 959,000 shares worth $6.76M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Aptose Biosciences, Inc., an estimated $5.22M trimmed.

  • Opaleye Management's largest Q4 2020 buy was Tricida, Inc. Common Stock: 959,000 shares worth $6.76M.
  • Opaleye Management added most to Ocular Therapeutix in Q4 2020, an estimated $7.81M increase.
  • Opaleye Management's biggest Q4 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $5.22M.
  • Opaleye Management fully exited Avenue Therapeutics, Inc. Common Stock in Q4 2020, selling an estimated $10.7M.
  • Opaleye Management's ten largest holdings make up 56% of its $766M portfolio in Q4 2020.
  • Opaleye Management opened 13 new positions and closed 9 in Q4 2020.
  • Opaleye Management's portfolio value rose 50% quarter-over-quarter to $766M.

Based on Opaleye Management's 13F filing for Q4 2020, filed 12 Feb 2021.